Brain iron pathways and their relevance to Parkinson's disease

A central role of iron in the pathogenesis of Parkinson's disease (PD), due to its increase in substantia nigra pars compacta dopaminergic neurons and reactive microglia and its capacity to enhance production of toxic reactive oxygen radicals, has been discussed for many years. Recent transcranial ultrasound findings and the observation of the ability of iron to induce aggregation and toxicity of α‐synuclein have reinforced the critical role of iron in the pathogenesis of nigrostriatal injury. Presently the mechanisms involved in the disturbances of iron metabolism in PD remain obscure. In this review we summarize evidence from recent studies suggesting disturbances of iron metabolism in PD at possibly different levels including iron uptake, storage, intracellular metabolism, release and post‐transcriptional control. Moreover we outline that the interaction of iron with other molecules, especially α‐synuclein, may contribute to the process of neurodegeneration. Because many neurodegenerative diseases show increased accumulation of iron at the site of neurodegeneration, it is believed that maintenance of cellular iron homeostasis is crucial for the viability of neurons.

[1]  M Gallorini,et al.  Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes , 2001, Journal of neurochemistry.

[2]  G Becker,et al.  Relationship of substantia nigra echogenicity and motor function in elderly subjects , 2001, Neurology.

[3]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[4]  E. Broussolle,et al.  Clinical report of three patients with hereditary hemochromatosis and movement disorders , 2000, Movement disorders : official journal of the Movement Disorder Society.

[5]  J. Tolmie,et al.  Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation , 2000 .

[6]  L. Greene,et al.  Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Horbinski,et al.  Differential Localization of Divalent Metal Transporter 1 with and without Iron Response Element in Rat PC12 and Sympathetic Neuronal Cells , 2000, The Journal of Neuroscience.

[8]  H. Schipper,et al.  Role of heme oxygenase‐1 in the regulation of manganese superoxide dismutase gene expression in oxidatively‐challenged astroglia , 2000, Journal of cellular physiology.

[9]  L. Benson,et al.  Iron-dependent self-assembly of recombinant yeast frataxin: implications for Friedreich ataxia. , 2000, American journal of human genetics.

[10]  John Hardy,et al.  The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity , 2000, The Journal of Neuroscience.

[11]  F. Kishi,et al.  Human NRAMP2/DMT1, Which Mediates Iron Transport across Endosomal Membranes, Is Localized to Late Endosomes and Lysosomes in HEp-2 Cells* , 2000, The Journal of Biological Chemistry.

[12]  S. Abboud,et al.  A Novel Mammalian Iron-regulated Protein Involved in Intracellular Iron Metabolism* , 2000, The Journal of Biological Chemistry.

[13]  M. Youdim,et al.  Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. , 2000, Cellular and molecular biology.

[14]  T. Wada,et al.  Tubular injury as a cardinal pathologic feature in human heme oxygenase-1 deficiency. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  E. Morgan,et al.  Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain. , 2000, Cellular and molecular biology.

[16]  B. Bergamasco,et al.  Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. , 2000, Biochimica et biophysica acta.

[17]  P. Ponka,et al.  Effects of Interferon-γ and Lipopolysaccharide on Macrophage Iron Metabolism Are Mediated by Nitric Oxide-induced Degradation of Iron Regulatory Protein 2* , 2000, The Journal of Biological Chemistry.

[18]  Y. Agid,et al.  Preservation of midbrain catecholaminergic neurons in very old human subjects. , 2000, Brain : a journal of neurology.

[19]  M. Núñez,et al.  Overexpression of the Ferritin Iron-responsive Element Decreases the Labile Iron Pool and Abolishes the Regulation of Iron Absorption by Intestinal Epithelial (Caco-2) Cells* , 2000, The Journal of Biological Chemistry.

[20]  J. Feder The hereditary hemochromatosis gene (HFE) , 1999, Immunologic research.

[21]  S. Mandel,et al.  The Pivotal Role of Iron in NF‐κB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators , 1999, Annals of the New York Academy of Sciences.

[22]  H. Beug,et al.  Post-transcriptional control via iron-responsive elements: the impact of aberrations in hereditary disease. , 1999, Mutation research.

[23]  M. Herman,et al.  Age-related hippocampal changes in Bcl-2:Bax ratio, oxidative stress, redox-active iron and apoptosis associated with aluminum-induced neurodegeneration: increased susceptibility with aging. , 1999, Neurotoxicology.

[24]  N. Andrews The iron transporter DMT1. , 1999, The international journal of biochemistry & cell biology.

[25]  E. Morgan,et al.  Iron-independent neuronal expression of transferrin receptor mRNA in the rat. , 1999, Brain research. Molecular brain research.

[26]  M E Conrad,et al.  Iron absorption and transport. , 1999, The American journal of the medical sciences.

[27]  D. Haile,et al.  Regulation of genes of iron metabolism by the iron-response proteins. , 1999, The American journal of the medical sciences.

[28]  D. Dexter,et al.  Lactoferrin is synthesized by mouse brain tissue and its expression is enhanced after MPTP treatment. , 1999, Advances in experimental medicine and biology.

[29]  J. Gitlin,et al.  Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  G Becker,et al.  Vulnerability of the nigrostriatal system as detected by transcranial ultrasound , 1999, Neurology.

[31]  Z. Wszolek,et al.  Reduced expression of the G209A α‐synuclein allele in familial parkinsonism , 1999 .

[32]  J. Snaedal,et al.  Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. , 1999, Pharmacology & toxicology.

[33]  M. G. Bridelli,et al.  The structure of neuromelanin and its iron binding site studied by infrared spectroscopy , 1999, FEBS letters.

[34]  G Becker,et al.  Iron accumulation in the substantia nigra in rats visualized by ultrasound. , 1999, Ultrasound in medicine & biology.

[35]  J Kim,et al.  Copper(II)-induced self-oligomerization of alpha-synuclein. , 1999, The Biochemical journal.

[36]  T. Lee,et al.  Time-course and localization of transferrin receptor expression in the substantia nigra of 6-hydroxydopamine-induced parkinsonian rats , 1999, Neuroscience.

[37]  M. Núñez,et al.  Transferrin stimulates iron absorption, exocytosis, and secretion in cultured intestinal cells. , 1999, The American journal of physiology.

[38]  L. Bernier,et al.  Mitochondrial Iron Sequestration in Dopamine‐Challenged Astroglia: Role of Heme Oxygenase‐1 and the Permeability Transition Pore , 1999, Journal of neurochemistry.

[39]  C. Levenson,et al.  Developmental regulation of hepatic ceruloplasmin mRNA and serum activity by exogenous thyroxine and dexamethasone. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[40]  C. Ríos,et al.  Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease , 1999, Neuroscience Letters.

[41]  P D Griffiths,et al.  Iron in the basal ganglia in Parkinson's disease. An in vitro study using extended X-ray absorption fine structure and cryo-electron microscopy. , 1999, Brain : a journal of neurology.

[42]  E. Masliah,et al.  Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro , 1999 .

[43]  W. Sly,et al.  Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  L. Fenart,et al.  Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier* , 1999, The Journal of Biological Chemistry.

[45]  P. Ponka,et al.  Cellular iron metabolism. , 1999, Kidney international. Supplement.

[46]  S. Grinstein,et al.  The Iron Transport Protein NRAMP2 Is an Integral Membrane Glycoprotein That Colocalizes with Transferrin in Recycling Endosomes , 1999, The Journal of experimental medicine.

[47]  D. Radisky,et al.  The Yeast Frataxin Homologue Mediates Mitochondrial Iron Efflux , 1999, The Journal of Biological Chemistry.

[48]  P Z Marmarelis,et al.  MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. , 1999, Magnetic resonance imaging.

[49]  V. Seshadri,et al.  Ceruloplasmin Ferroxidase Activity Stimulates Cellular Iron Uptake by a Trivalent Cation-specific Transport Mechanism* , 1999, The Journal of Biological Chemistry.

[50]  J. Yu,et al.  Characterization and chromosomal mapping of the human gene for SFT, a stimulator of Fe transport. , 1998, Biochemical and biophysical research communications.

[51]  J. Dooley,et al.  Monocyte-macrophage ferric reductase activity is inhibited by iron and stimulated by cellular differentiation. , 1998, The Biochemical journal.

[52]  J. Feder,et al.  Co-trafficking of HFE, a Nonclassical Major Histocompatibility Complex Class I Protein, with the Transferrin Receptor Implies a Role in Intracellular Iron Regulation* , 1998, The Journal of Biological Chemistry.

[53]  Jianming Yu,et al.  Structural and Functional Analysis of SFT, a Stimulator of Fe Transport* , 1998, The Journal of Biological Chemistry.

[54]  G. Minotti,et al.  Effect of Reactive Oxygen Species on Iron Regulatory Protein Activity a , 1998, Annals of the New York Academy of Sciences.

[55]  P. Riederer,et al.  In Vitro Studies of Ferritin Iron Release and Neurotoxicity , 1998, Journal of neurochemistry.

[56]  R. Crowther,et al.  α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .

[57]  P. Bjorkman,et al.  Crystal Structure of the Hemochromatosis Protein HFE and Characterization of Its Interaction with Transferrin Receptor , 1998, Cell.

[58]  J. Kaplan,et al.  Iron and copper transport in yeast and its relevance to human disease. , 1998, Trends in biochemical sciences.

[59]  U. Muthane,et al.  Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India , 1998, Annals of neurology.

[60]  E. Stopa,et al.  Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease , 1998, Experimental Neurology.

[61]  D. M. Penny,et al.  The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[62]  A. Takeda,et al.  Evidence for non‐transferrin‐mediated uptake and release of iron and manganese in glial cell cultures from hypotransferrinemic mice , 1998, Journal of neuroscience research.

[63]  Y. Mizuno,et al.  Apoptosis in neurodegenerative disorders. , 1998, Internal medicine.

[64]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[65]  P. Fox,et al.  Role of ceruloplasmin in cellular iron uptake. , 1998, Science.

[66]  Jianming Yu,et al.  Functional Expression Cloning and Characterization of SFT, a Stimulator of Fe Transport , 1997, The Journal of cell biology.

[67]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[68]  R E Burke,et al.  Apoptosis in neurodegenerative disorders. , 1997, Current opinion in neurology.

[69]  Stephan Nussberger,et al.  Cloning and characterization of a mammalian proton-coupled metal-ion transporter , 1997, Nature.

[70]  S. Young,et al.  Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells , 1997, FEBS letters.

[71]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[72]  P Riederer,et al.  Iron in the Parkinsonian substantia nigra. , 1997, Movement disorders : official journal of the Movement Disorder Society.

[73]  E. Hirsch,et al.  The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease , 1997, Brain Research.

[74]  M. Mattson,et al.  Intraneuronal aluminum potentiates iron-induced oxidative stress in cultured rat hippocampal neurons , 1996, Brain Research.

[75]  J. Gitlin,et al.  Expression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. , 1996, Human molecular genetics.

[76]  P. Lewitt,et al.  Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders , 1996, Brain Research.

[77]  H. Clevers,et al.  Defective iron homeostasis in beta 2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man , 1996, The Journal of experimental medicine.

[78]  H. Feldman,et al.  Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.

[79]  M. Hentze,et al.  Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[80]  H. M. Swartz,et al.  Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.

[81]  S. LeVine,et al.  The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry. , 1996, Brain research. Developmental brain research.

[82]  H. Schipper Astrocytes, brain aging, and neurodegeneration , 1996, Neurobiology of Aging.

[83]  F. Ye,et al.  Basal ganglia iron content in Parkinson's disease measured with magnetic resonance , 1996, Movement disorders : official journal of the Movement Disorder Society.

[84]  T. O’Halloran,et al.  Iron Metabolism in Eukaryotes—Mars and Venus at It Again , 1996, Science.

[85]  W. Jefferies,et al.  Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin , 1996, Brain Research.

[86]  W. Jefferies,et al.  Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium , 1996, Brain Research.

[87]  Y Agid,et al.  Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[88]  W. Jefferies,et al.  A novel iron uptake mechanism mediated by GPI‐anchored human p97. , 1995, The EMBO journal.

[89]  P. Riederer,et al.  Mössbauer Spectroscopic Studies of Purified Human Neuromelanin Isolated from the Substantia Nigra , 1995, Journal of neurochemistry.

[90]  T. Sarna,et al.  The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.

[91]  E. Stopa,et al.  Expression of heme oxygenase‐1 in the senescent and alzheimer‐diseased brain , 1995, Annals of neurology.

[92]  P. Ryvlin,et al.  Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. , 1995, Archives of neurology.

[93]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[94]  S. Hirai,et al.  Activated microglia cause superoxide-mediated release of iron from ferritin , 1995, Neuroscience Letters.

[95]  H. Schipper,et al.  A Cellular Stress Model for the Sequestration of Redox‐Active Glial Iron in the Aging and Degenerating Nervous System , 1995, Journal of neurochemistry.

[96]  R. MacGillivray,et al.  Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[97]  G Becker,et al.  Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography , 1995, Neurology.

[98]  J. Edwardson,et al.  Transferrin receptors in the Parkinsonian midbrain , 1994, Neuropathology and applied neurobiology.

[99]  P. Riederer,et al.  Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.

[100]  K. Jellinger,et al.  Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.

[101]  S. Benkovic,et al.  Isoforms of ferritin have a specific cellular distribution in the brain , 1994, Journal of neuroscience research.

[102]  D. Radice,et al.  Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.

[103]  Y. Wada,et al.  Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. , 1993, American journal of human genetics.

[104]  P. Boesiger,et al.  T2 relaxation time in patients with Parkinson's disease , 1993, Neurology.

[105]  F. Real,et al.  Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. , 1993, Journal of cell science.

[106]  R. Klausner,et al.  Regulating the fate of mRNA: The control of cellular iron metabolism , 1993, Cell.

[107]  R. Simpson,et al.  Rate of 59Fe Uptake into Brain and Cerebrospinal Fluid and the Influence Thereon of Antibodies Against the Transferrin Receptor , 1993, Journal of neurochemistry.

[108]  C. W. Olanow,et al.  Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.

[109]  K. Jellinger,et al.  Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.

[110]  C. Morris,et al.  Uptake and Distribution of Iron and Transferrin in the Adult Rat Brain , 1992, Journal of neurochemistry.

[111]  C. Olanow Magnetic resonance imaging in parkinsonism. , 1992, Neurologic clinics.

[112]  H. Baker,et al.  Human melanotransferrin (p97) has only one functional iron‐binding site , 1992, FEBS letters.

[113]  E. Parati,et al.  The chemical characterization of melanin contained in substantia nigra of human brain. , 1992, Biochimica et biophysica acta.

[114]  J. Serody,et al.  Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation. , 1991, Journal of immunology.

[115]  P. Riederer,et al.  Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease , 1991, Journal of neurochemistry.

[116]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[117]  Birgens Hs The interaction of lactoferrin with human monocytes. , 1991 .

[118]  W. Gibb,et al.  Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[119]  L. Schiaffonati,et al.  Expression of the genes for the ferritin H and L subunits in rat liver and heart. Evidence for tissue-specific regulations at pre- and post-translational levels. , 1991, The Biochemical journal.

[120]  H J Gundersen,et al.  The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[121]  J. Connor,et al.  Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains , 1990, Journal of neuroscience research.

[122]  L. Davidson,et al.  Fe-saturation and proteolysis of human lactoferrin: effect on brush-border receptor-mediated uptake of Fe and Mn. , 1989, The American journal of physiology.

[123]  D. Rice,et al.  Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 A resolution. , 1989, Journal of molecular biology.

[124]  C. Marsden,et al.  Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease , 1989, Journal of neurochemistry.

[125]  E. Mukai,et al.  [Magnetic resonance imaging of parkinsonism]. , 1989, Rinsho shinkeigaku = Clinical neurology.

[126]  Peter Riederer,et al.  Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.

[127]  S. Aust,et al.  Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. , 1989, The Journal of biological chemistry.

[128]  W. Banks,et al.  Studies of the slow bidirectional transport of iron and transferrin across the blood-brain barrier , 1988, Brain Research Bulletin.

[129]  E. Schon,et al.  Nonidentical distribution of transferrin and ferric iron in human brain , 1988, Neuroscience.

[130]  A. Graybiel,et al.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease , 1988, Nature.

[131]  Y. Yamada,et al.  Lactoferrin binding by leukemia cell lines. , 1987, Blood.

[132]  B. Halliwell,et al.  Iron and free radical reactions: two aspects of antioxidant protection , 1986 .

[133]  S. Snyder,et al.  Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.

[134]  David M. A. Mann,et al.  Possible role of neuromelanin in the pathogenesis of Parkinson's disease , 1983, Mechanisms of Ageing and Development.

[135]  R. Johnston,et al.  Lactoferrin enhances hydroxyl radical production by human neutrophils, neutrophil particulate fractions, and an enzymatic generating system. , 1981, The Journal of clinical investigation.

[136]  J. Hajdu,et al.  Proteolysis of human ceruloplasmin. Some peptide bonds are particularly susceptible to proteolytic attack. , 1979, European journal of biochemistry.

[137]  S. Murao,et al.  HEMOCHROMATOSIS ASSOCIATED WITH BRAIN LESIONS: A DISORDER OF TRACE‐METAL BINDING PROTEINS AND/OR POLYMERS? , 1977, Journal of neuropathology and experimental neurology.

[138]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[139]  P. Aisen,et al.  Lactoferrin and transferrin: a comparative study. , 1972, Biochimica et biophysica acta.

[140]  B. Hallgren,et al.  THE EFFECT OF AGE ON THE NON‐HAEMIN IRON IN THE HUMAN BRAIN , 1958, Journal of neurochemistry.

[141]  R. G. Simpson,et al.  The benzidine test for occult blood in faces. , 1952, The Quarterly journal of medicine.

[142]  J. Cammermeyer DEPOSITION OF IRON IN PARAVENTRICULAR AREAS OF THE HUMAN BRAIN IN HEMOCHROMATOSIS , 1947 .

[143]  J. Sheldon The Iron Content of the Tissues in Haemochromatosis, With Special Reference to the Brain , 1927 .

[144]  D. Berg,et al.  The basal ganglia in haemochromatosis , 2000, Neuroradiology.

[145]  Elizabeth C. Theil Targeting mRNA to regulate iron and oxygen metabolism. , 2000, Biochemical pharmacology.

[146]  J. Tolmie,et al.  Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturation. , 2000, Blood.

[147]  E. Leibold,et al.  Regulation of the iron regulatory proteins by reactive nitrogen and oxygen species. , 1999, Gene expression.

[148]  F. Jiménez-Jiménez,et al.  Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease , 1998, Journal of Neural Transmission.

[149]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[150]  T. Shima,et al.  Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.

[151]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[152]  P. Hof,et al.  Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson’s disease cases , 1996, Acta Neuropathologica.

[153]  R. Thach,et al.  Regulation of iron metabolism: translational effects mediated by iron, heme, and cytokines. , 1995, Annual review of nutrition.

[154]  K. Krabbe,et al.  Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[155]  P. Riederer,et al.  Intranigral injected iron progressively reduces striatal dopamine metabolism , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[156]  P. Riederer,et al.  The enigma of neuromelanin in Parkinson's disease substantia nigra. , 1994, Journal of neural transmission. Supplementum.

[157]  G. Mashour,et al.  Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. , 1994, Alzheimer disease and associated disorders.

[158]  P Riederer,et al.  The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. , 1993, Advances in neurology.

[159]  C. Marsden,et al.  Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. , 1993, Advances in neurology.

[160]  望月 秀樹 Iron-melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture , 1993 .

[161]  H. M. Swartz,et al.  Total and paramagnetic metals in human substantia nigra and its neuromelanin , 1993, Journal of neural transmission. Parkinson's disease and dementia section.

[162]  C. Marsden,et al.  Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease , 1992, Annals of neurology.

[163]  T. Sarna,et al.  Modulation by neuromelanin of the availability and reactivity of metal ions , 1992, Annals of neurology.

[164]  K. Jellinger,et al.  Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease , 1992, Annals of neurology.

[165]  J. Connor,et al.  Iron regulation in the brain: Histochemical, biochemical, and molecular considerations , 1992, Annals of neurology.

[166]  G. Cesareni,et al.  Structural and functional studies of human ferritin H and L chains. , 1991, Current studies in hematology and blood transfusion.

[167]  H. Birgens The interaction of lactoferrin with human monocytes. , 1991, Danish medical bulletin.

[168]  K. Jellinger,et al.  Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.

[169]  P. Riederer,et al.  Biochemical fundamentals of Parkinson's disease. , 1988, The Mount Sinai journal of medicine, New York.

[170]  J. Drysdale,et al.  Human ferritin gene expression. , 1988, Progress in nucleic acid research and molecular biology.

[171]  T. Sarna,et al.  The effect of melanin on iron associated decomposition of hydrogen peroxide. , 1988, Free radical biology & medicine.

[172]  Elizabeth C. Theil Ferritin: structure, gene regulation, and cellular function in animals, plants, and microorganisms. , 1987, Annual review of biochemistry.

[173]  T. Bothwell,et al.  Iron absorption. , 1983, Annual review of medicine.

[174]  P. Mcgeer,et al.  Aging and extrapyramidal function. , 1977, Archives of neurology.

[175]  P. Yates,et al.  Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. , 1974, Brain : a journal of neurology.

[176]  A. Boujnah [IRON METABOLISM]. , 1964, La Tunisie medicale.

[177]  J. Cammermyer Deposition of iron in paraventricular areas of the human brain in hemochromatosis. , 1947, Journal of neuropathology and experimental neurology.